Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;105(4):864-869.
doi: 10.3324/haematol.2019.233320. Epub 2020 Mar 19.

Myelodysplastic syndrome patient-derived xenografts: from no options to many

Christophe Côme  1   2   3 , Alexander Balhuizen  1   2   3 , Dominique Bonnet  4 , Bo T Porse  5   2   3
Affiliations

Myelodysplastic syndrome patient-derived xenografts: from no options to many

Christophe Côme et al. Haematologica. 2020 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Key features of published and alternative patient-derived xenograft models of myelodysplastic syndrome. The left panel depicts the sources of cells from patients with myelodysplastic syndrome (MDS) which are injected to generate MDS patient-derived xenografts. Tumor cells (red circles) are constituted of bone marrow (BM) cells, mononuclear cells (MNC), or CD34+ purified or T-cell depleted BM cells. Supporting cells (yellow) are BM-derived mesenchymal stromal cells (MSC) derived from patients or healthy donors. The time periods for ossicle development and engraftment of MDS cells are illustrated by light and dark gray bars, respectively. The time of conditioning of the animal, by either irradiation or busulfan treatment is indicated, and the injection route is illustrated by a syringe.
See this image and copyright information in PMC

References

    1. Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. 2016;127(20):2391–2405. - PubMed
    1. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–3627. - PMC - PubMed
    1. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241–247. - PMC - PubMed
    1. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. - PMC - PubMed
    1. Strupp C, Nachtkamp K, Hildebrandt B, et al. New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types. Leuk Res. 2017;57:78–84. - PubMed

Publication types